Arcutis Biotherapeutics Inc
ARQT14.355USD
+0.065+0.45%
Market hours （ET）Quotes delayed by 15 min
1.71BMarket Cap
LossP/E TTM
More Details of Arcutis Biotherapeutics Inc Company
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Company Info
Ticker SymbolARQT
Company nameArcutis Biotherapeutics Inc
IPO dateJan 31, 2020
CEOMr. Todd Franklin Watanabe
Number of employees342
Security typeOrdinary Share
Fiscal year-endJan 31
Address3027 Townsgate Road
CityWESTLAKE VILLAGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91361
Phone18054185006
Websitehttps://arcutis.com/
Ticker SymbolARQT
IPO dateJan 31, 2020
CEOMr. Todd Franklin Watanabe
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
26.43K
+40.42%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.24%
Investment Advisor/Hedge Fund
31.96%
Hedge Fund
29.96%
Private Equity
7.39%
Research Firm
4.30%
Individual Investor
2.19%
Venture Capital
1.84%
Sovereign Wealth Fund
0.45%
Bank and Trust
0.42%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
477
132.39M
111.07%
-21.95M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Simplify Health Care ETF
4.4%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
SPDR S&P Biotech ETF
0.55%
First Trust Small Cap Growth AlphaDEX Fund
0.49%
Direxion Daily S&P Biotech Bull 3X Shares
0.31%
Federated Hermes MDT Small Cap Core ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.27%
ProShares Ultra Nasdaq Biotechnology
0.19%
Invesco Nasdaq Biotechnology ETF
0.19%
Inspire Small/Mid Cap ESG ETF
0.17%
View more
Simplify Health Care ETF
Proportion4.4%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.93%
SPDR S&P Biotech ETF
Proportion0.55%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.49%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.31%
Federated Hermes MDT Small Cap Core ETF
Proportion0.28%
First Trust Small Cap Core Alphadex Fund
Proportion0.27%
ProShares Ultra Nasdaq Biotechnology
Proportion0.19%
Invesco Nasdaq Biotechnology ETF
Proportion0.19%
Inspire Small/Mid Cap ESG ETF
Proportion0.17%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
